UBS Analyst Comments on Vertex's Combination Regimen

UBS analyst Matthew Roden said in a note today that the Lumacaftor, Ivacaftor combination regimen could fetch as much as $150 thousand per patient per year.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorNewsAnalyst RatingsMattew RodenUBS
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!